SAB Biotherapeutics jumps on FDA's 'fast track' tag for influenza therapy

SAB Biotherapeutics

13/04/2023 13:54

** Shares of SAB Biotherapeutics Inc  SABS.O  more than
double at 81 cents before the bell 
    ** U.S. FDA grants "fast track" designation for its
influenza therapy, SAB-176
    ** "Fast track" tag facilitates the development and expedite
the review of drug candidates intended to treat serious
conditions
    ** FDA greenlights manufacturing approach for therapy to
address influenza strain change - Co
    ** Adds it also received FDA guidance and regulatory
alignment on advancing the therapy into further development,
including a mid-stage trial study design
    ** SAB-176, is an immunotherapy being developed to
neutralize Type A and Type B influenza viruses, which mutate
rapidly
    ** YTD stock down 35.6%, as of last close 

 (Reporting by Pratik Jain in Bengaluru)
 ((Pratik.Jain@thomsonreuters.com;))